Prognostic Value of MiR-155 in Individuals with Monoclonal B-cell Lymphocytosis and Patients with B Chronic Lymphocytic Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jul 4

PMID 23821659

Citations 105

Authors

Alessandra Ferrajoli

Tait D Shanafelt

Cristina Ivan

Masayoshi Shimizu

Kari G Rabe

Nazila Nouraee

Mariko Ikuo

Asish K Ghosh

Susan Lerner

Laura Z Rassenti

Lianchun Xiao

Jianhua Hu

James M Reuben

Steliana Calin

M James You

John T Manning

William G Wierda

Zeev Estrov

Susan OBrien

Thomas J Kipps

Michael J Keating

Neil E Kay

George A Calin

Affiliations

Soon will be listed here.

Abstract

Noncoding RNAs play a pivotal role in the pathogenesis of chronic lymphocytic leukemia (CLL). We hypothesized that microRNAs (miRs) are involved in the transition from monoclonal B-cell lymphocytosis (MBL) to CLL and tested miR-15a/16-1 cluster, miR-21, and miR-155 expression in purified B cells of normal individuals, individuals with MBL, and patients with CLL. When we analyzed 224 samples from 2 independent training and validation cohorts, we found that miR-155 was overexpressed in B cells from individuals with MBL, and even more so in B cells from patients with CLL, when compared with B cells from normal individuals. Furthermore, we were able to identify miR-155 in circulating microvesicles from both individuals with MBL and patients with CLL. Next, to examine the prognostic role of miR-155, we measured its expression level in plasma samples collected before treatment initiation in 228 patients with CLL. We found significantly higher miR-155 expression levels in patients who failed to achieve a complete response compared with those who experienced complete response. Our findings support the use of cellular and plasma levels of miR-155 as biomarkers for the risk of progression in individuals with MBL, as well as to identify patients with CLL who may not respond well to therapy.

Citing Articles

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.

Koumpis E, Georgoulis V, Papathanasiou K, Papoudou-Bai A, Kanavaros P, Kolettas E Biomedicines. 2025; 12(12.

PMID: 39767565 PMC: 11673977. DOI: 10.3390/biomedicines12122658.

The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.

Dysregulated MicroRNAs in Chronic Lymphocytic Leukemia.

Mesaros O, Veres S, Onciul M, Matei E, Jimbu L, Neaga A Cureus. 2024; 16(9):e68770.

PMID: 39376808 PMC: 11456419. DOI: 10.7759/cureus.68770.

MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.

Golovina E, Heizer T, Daumova L, Bajecny M, Fontana S, Griggio V Cancer Cell Int. 2024; 24(1):251.

PMID: 39020347 PMC: 11256420. DOI: 10.1186/s12935-024-03437-8.

References

Moussay E, Wang K, Cho J, Van Moer K, Pierson S, Paggetti J . MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2011; 108(16):6573-8. PMC: 3081030. DOI: 10.1073/pnas.1019557108. View

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

Fonte E, Apollonio B, Scarfo L, Ranghetti P, Fazi C, Ghia P . In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors. Clin Cancer Res. 2012; 19(2):367-79. DOI: 10.1158/1078-0432.CCR-12-1922. View

Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M . Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2011; 5(3):492-497. PMC: 4186243. DOI: 10.1158/1940-6207.CAPR-11-0370. View

Rassenti L, Jain S, Keating M, Wierda W, Grever M, Byrd J . Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008; 112(5):1923-30. PMC: 2518894. DOI: 10.1182/blood-2007-05-092882. View

Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S . Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007; 109(11):4944-51. DOI: 10.1182/blood-2006-12-062398. View

Wang M, Tan L, Dijkstra M, van Lom K, Robertus J, Harms G . miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol. 2008; 215(1):13-20. DOI: 10.1002/path.2333. View

Tam C, OBrien S, Wierda W, Kantarjian H, Wen S, Do K . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4):975-80. PMC: 3952498. DOI: 10.1182/blood-2008-02-140582. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

10.

Badoux X, Keating M, Wang X, OBrien S, Ferrajoli A, Faderl S . Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011; 117(11):3016-24. PMC: 4123386. DOI: 10.1182/blood-2010-08-304683. View

11.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

12.

Rawstron A, Bennett F, OConnor S, Kwok M, Fenton J, Plummer M . Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6):575-83. DOI: 10.1056/NEJMoa075290. View

13.

Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M . MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One. 2009; 4(10):e7405. PMC: 2756627. DOI: 10.1371/journal.pone.0007405. View

14.

Martinez M, Larbret F, Zobairi F, Coulombe J, Debili N, Vainchenker W . Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood. 2006; 108(9):3012-20. DOI: 10.1182/blood-2006-04-019109. View

15.

Stilgenbauer S, Zenz T . Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2010:481-8. DOI: 10.1182/asheducation-2010.1.481. View

16.

Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J . The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2002; 1(1):53-66. DOI: 10.1038/sj.thj.6200013. View

17.

Wierda W, OBrien S, Wang X, Faderl S, Ferrajoli A, Do K . Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009; 27(10):1637-43. PMC: 4890649. DOI: 10.1200/JCO.2008.18.1701. View

18.

Shanafelt T, Kay N, Jenkins G, Call T, Zent C, Jelinek D . B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 2008; 113(18):4188-96. PMC: 2676080. DOI: 10.1182/blood-2008-09-176149. View

19.

Dewald G, Brockman S, Paternoster S, Bone N, OFallon J, Allmer C . Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003; 121(2):287-95. DOI: 10.1046/j.1365-2141.2003.04265.x. View

20.

Ambros V . microRNAs: tiny regulators with great potential. Cell. 2002; 107(7):823-6. DOI: 10.1016/s0092-8674(01)00616-x. View